# Sodium Selenite as a Cytotoxic Agent in Advanced Carcinoma

> **NCT01959438** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Karolinska University Hospital** · enrollment: 32 (estimated)

## Conditions studied

- Malignant Tumor
- Treatment Resistant Disorders
- Tumor Progression

## Interventions

- **DRUG:** Sodium selenite (Introselen)
- **DRUG:** Sodium selenite

## Key facts

- **NCT ID:** NCT01959438
- **Lead sponsor:** Karolinska University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-02
- **Primary completion:** 2016-10
- **Final completion:** 2018-06
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2013-10-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01959438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01959438, "Sodium Selenite as a Cytotoxic Agent in Advanced Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01959438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*